{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:27:19Z","timestamp":1792643239649,"version":"4.5.0"},"reference-count":40,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Guideline\u2010directed medical therapy (GDMT) is designed to improve clinical outcomes. The study aim was to assess GDMT prescribing rates and prescribing\u2010persistence predictors in patients with diabetes and chronic kidney disease (CKD) from the Center for Kidney Disease Research, Education, and Hope Registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Data were obtained from adults \u226518\u2009years old with diabetes and CKD between 1 January 2019 and 31 December 2020 (N\u2009=\u200939\u2009158). Baseline and persistent (\u226590\u2009days) prescriptions for GDMT, including angiotensin converting enzyme (ACE) inhibitor\/angiotensin receptor blocker (ARB), sodium\u2010glucose cotransporter\u20102 (SGLT2) inhibitor and glucagon\u2010like peptide 1 (GLP\u20101) receptor agonist were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The population age (mean\u2009\u00b1\u2009SD) was 70\u2009\u00b1\u200914\u2009years, and 49.6% (n\u2009=\u200919\u2009415) were women. Baseline estimated glomerular filtration rate (2021 CKD\u2010Epidemiology Collaboration creatinine equation) was 57.5\u2009\u00b1\u200923.0\u2009ml\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      and urine albumin\/creatinine 57.5\u2009mg\/g (31.7\u2010158.2; median, interquartile range). Baseline and \u226590\u2010day persistent prescribing rates, respectively, were 70.7% and 40.4% for ACE inhibitor\/ARB, 6.0% and 5.0% for SGLT2 inhibitors, and 6.8% and 6.3% for GLP\u20101 receptor agonist (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001). Patients lacking primary commercial health insurance coverage were less likely to be prescribed an ACE inhibitor\/ARB [odds ratio (OR)\u2009=\u20090.89; 95% confidence interval (CI) 0.84\u20100.95;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001], SGLT2 inhibitor (OR 0.72; 95% CI 0.64\u20100.81;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001) or GLP\u20101 receptor agonist (OR 0.89; 95% CI 0.80\u20100.98;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.02). GDMT prescribing rates were lower at Providence than UCLA Health.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prescribing for GDMT was suboptimal and waned quickly in patients with diabetes and CKD. Type of primary health insurance coverage and health system were associated with GDMT prescribing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15194","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T06:47:08Z","timestamp":1688366828000},"page":"2970-2979","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Prescription of guideline\u2010directed medical therapies in patients with diabetes and chronic kidney disease from the\n                    <scp>CURE\u2010CKD<\/scp>\n                    Registry, 2019\u20102020"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3535-9120","authenticated-orcid":false,"given":"Susanne B.","family":"Nicholas","sequence":"first","affiliation":[{"name":"Nephrology Division, David Geffen School of Medicine University of California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenn B.","family":"Daratha","sequence":"additional","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest  Spokane Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5437-5700","authenticated-orcid":false,"given":"Radica Z.","family":"Alicic","sequence":"additional","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest  Spokane Washington USA"},{"name":"Department of Medicine University of Washington, Seattle  Spokane Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cami R.","family":"Jones","sequence":"additional","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest  Spokane Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey M.","family":"Kornowske","sequence":"additional","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest  Spokane Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest  Spokane Washington USA"},{"name":"Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences Washington State University  Spokane Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Fatoba","sequence":"additional","affiliation":[{"name":"Bayer US, LLC, Medical Affairs  Whippany Whippany USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon X.","family":"Kong","sequence":"additional","affiliation":[{"name":"Bayer US, LLC, Medical Affairs  Whippany Whippany USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Singh","sequence":"additional","affiliation":[{"name":"Bayer US, LLC, Medical Affairs  Whippany Whippany USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith C.","family":"Norris","sequence":"additional","affiliation":[{"name":"Nephrology Division, David Geffen School of Medicine University of California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest  Spokane Washington USA"},{"name":"Department of Medicine University of Washington, Seattle  Spokane Washington USA"},{"name":"Kidney Research Institute, Institute of Translational Health Sciences University of Washington  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Chronic Kidney Disease in the United States, 2021","author":"Centers for Disease Control and Prevention","year":"2021"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0529"},{"issue":"4","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"KDIGO","year":"2020","journal-title":"Kidney Int"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-015-3452-x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-015-0154-x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479481"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-01852-3"},{"key":"e_1_2_10_10_1","first-page":"S3","article-title":"Etiopathogenesis of kidney disease in minority populations and an updated special focus on treatment in diabetes and hypertension","volume":"114","author":"Umeukeje EM","year":"2022","journal-title":"J Natl Med Assoc"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01026-2"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108204"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jch.13563"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000475"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.08.018"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18169"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1558-9"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13510"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0614"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1815"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018100971"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01154-w"},{"key":"e_1_2_10_26_1","unstructured":"Equator Network.The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement; guidelines for reporting observational studies.2022. Accessed June 6 2022.http:\/\/www.equator-network.org\/reporting-guidelines\/strobe"},{"key":"e_1_2_10_27_1","first-page":"E110","article-title":"Construction of a multisite DataLink using electronic health records for the identification, surveillance, prevention, and management of diabetes mellitus: the SUPREME\u2010DM project","volume":"9","author":"Nichols GA","year":"2012","journal-title":"Prev Chronic Dis"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956"},{"key":"e_1_2_10_31_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2022"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-021-00504-9"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2014034"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.05.031"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa300"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6139"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2013.07.002"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.644"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2015.1005074"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-020-01369-x"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2022.05.003"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:43:25Z","timestamp":1761864205000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/dom.15194"],"URL":"https:\/\/doi.org\/10.1111\/dom.15194","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.15194\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15194\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15194\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15194\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15194\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15194\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15194\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15194\/v2\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"2023-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}